open access

Vol 8, No 6 (2012)
Guidelines / Expert consensus
Published online: 2013-01-24
Get Citation

Chemotherapy dosing in obese patients. Current position of the Committee for Clinical Initiatives of the Polish Society of Clinical Oncology

Piotr Jan Wysocki, Piotr Potemski, Maria Litwiniuk, Marzena Wełnicka-Jaśkiewicz, Krzysztof Krzemieniecki, Jan Walewski, Maciej Krzakowski
Onkol. Prak. Klin 2012;8(6):234-237.

open access

Vol 8, No 6 (2012)
EXPERTS' OPINION
Published online: 2013-01-24

Abstract

Overweight and obesity represent an important epidemiological problem. Also among cancer patients
the incidence of these metabolic conditions is continuously increasing. The dosage of chemotherapy
drugs is usually calculated according to patient’s body surface area (BSA). However, many oncologist
consider to use either ideal body weight or adjusted ideal body weight or to cap the BSA at, for example
2.0 m2 rather than use actual body weight to calculate BSA. It leads to inappropriate dosage of cytotoxic
drugs in obese or overweight patients whose BSA exceeds 2 m2 that may decrease the efficacy of
systemic treatment and worsen patients’ outcomes. The following article reflects the position of Polish
Society of Clinical Oncology (PTOK) regarding the recently published guidelines of American Society
of Clinical Oncology on appropriate chemotherapy dosing for obese adult patients with cancer. PTOK recommends that full weight-based cytotoxic chemotherapy doses be used to treat obese patients with
cancer, particularly when the goal of treatment is cure.

Abstract

Overweight and obesity represent an important epidemiological problem. Also among cancer patients
the incidence of these metabolic conditions is continuously increasing. The dosage of chemotherapy
drugs is usually calculated according to patient’s body surface area (BSA). However, many oncologist
consider to use either ideal body weight or adjusted ideal body weight or to cap the BSA at, for example
2.0 m2 rather than use actual body weight to calculate BSA. It leads to inappropriate dosage of cytotoxic
drugs in obese or overweight patients whose BSA exceeds 2 m2 that may decrease the efficacy of
systemic treatment and worsen patients’ outcomes. The following article reflects the position of Polish
Society of Clinical Oncology (PTOK) regarding the recently published guidelines of American Society
of Clinical Oncology on appropriate chemotherapy dosing for obese adult patients with cancer. PTOK recommends that full weight-based cytotoxic chemotherapy doses be used to treat obese patients with
cancer, particularly when the goal of treatment is cure.
Get Citation

Keywords

obesity; overweight; cancer; chemotherapy dosing; BSA

About this article
Title

Chemotherapy dosing in obese patients. Current position of the Committee for Clinical Initiatives of the Polish Society of Clinical Oncology

Journal

Oncology in Clinical Practice

Issue

Vol 8, No 6 (2012)

Article type

Guidelines / Expert consensus

Pages

234-237

Published online

2013-01-24

Bibliographic record

Onkol. Prak. Klin 2012;8(6):234-237.

Keywords

obesity
overweight
cancer
chemotherapy dosing
BSA

Authors

Piotr Jan Wysocki
Piotr Potemski
Maria Litwiniuk
Marzena Wełnicka-Jaśkiewicz
Krzysztof Krzemieniecki
Jan Walewski
Maciej Krzakowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl